Pharmaceutical Commerce - July/August 2009

Under the theme of personalized medicine, in vitro diagnostics will play an increasingly important role in new drug entries and new therapies

Better internal collaboration within companies is critical to improving the vital physician-rep relationship

As legislative mandates have receded, manufacturers must undertake their own initiatives for protecting against counterfeits and diversion

Specific, technology-based anticounterfeiting measures are a tactical response to a strategic problem. Holistic prevention strategies are needed

Blister card container has consumer-friendly features

Industry survey shows strengths and weaknesses of current IT support of supply chains

How to correlate plant performance to business performance

Oncology drug development pipelines are overflowing, but the sky-high prices of these agents are turning reimbursement schemes, and the very practice of cancer medicine, on their heads

Digital systems are changing the economics and functionality of scheduling and production of printed packaging

What keeps the pharma industry from getting its patient-safety message right?

LOOKING AHEAD . . .

New technological capabilities will enable management of sample-distribution processes to keep up with a challenging environment

2009 PDMA SHARING CONFERENCE EXHIBITORS

Health Mart franchise network is now over 2,300 independent pharmacies

Purchase adds mobile content delivery to PI’s slate of communications services

The most basic impulse behind CER is the desire to control healthcare costs. The implications for the biopharma industry could be significant

Are you prepared?

Preventable medical and medication errors should figure more prominently in the current debate on healthcare reform

Central nervous system (CNS) medication for society’s oldest and youngest present special challenges

A fast-growing market supports more, and more comprehensive, data services

In whatever form biosimilar legislation might take, patent holders will need to review their patent portfolios carefully

Deloitte’s annual study of information security trends finds gaping holes in network security

Five steps to take when the duty for developing Risk Evaluation and Mitigation Strategies (REMS) is imposed on commercial operations

IMS Health rolls out Global Message IQ service for syndicated market research

Apriso’s FlexNet software to help trace RFID-tagged plasma throughout supply chain

California pedigree delay proves fatal to pioneering IT firm

Biggest focus remains oncologic/immunologic and CNS drugs; about one in six candidates eventually gain approval, according to Tufts study

Approval marks an innovative buccal drug-delivery mechanism, as well as signaling how FDA might approach REMS for all opioids

Moisture control, time-temperature monitoring are among the application areas being driven by biotech products and others, says Freedonia Group